Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic Inflammation in Preclinical Ulcerative Colitis.
Bergemalm D, Andersson E, Hultdin J, Eriksson C, Rush ST, Kalla R, Adams AT, Keita ÅV, D'Amato M, Gomollon F, Jahnsen J; IBD Character Consortium; Ricanek P, Satsangi J, Repsilber D, Karling P, Halfvarson J. Bergemalm D, et al. Among authors: eriksson c. Gastroenterology. 2021 Nov;161(5):1526-1539.e9. doi: 10.1053/j.gastro.2021.07.026. Epub 2021 Jul 21. Gastroenterology. 2021. PMID: 34298022 Free article.
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C; SWIBREG Vedolizumab Study Group; Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig E, Strid H, Ludvigsson JF, Almer S, Halfvarson J. Eriksson C, et al. Scand J Gastroenterol. 2017 Jun-Jul;52(6-7):722-729. doi: 10.1080/00365521.2017.1304987. Epub 2017 Mar 31. Scand J Gastroenterol. 2017. PMID: 28362144
Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Rundquist S, Eriksson C, Nilsson L, Angelison L, Jäghult S, Björk J, Grip O, Hjortswang H, Strid H, Karlén P, Montgomery S, Halfvarson J. Rundquist S, et al. Among authors: eriksson c. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1257-1263. doi: 10.1080/00365521.2018.1519597. Epub 2018 Oct 24. Scand J Gastroenterol. 2018. PMID: 30353751
The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
Shrestha S, Olén O, Eriksson C, Everhov ÅH, Myrelid P, Visuri I, Ludvigsson JF, Schoultz I, Montgomery S, Sachs MC, Halfvarson J; SWIBREG Study Group; Olsson M, Hjortswang H, Bengtsson J, Strid H, Andersson M, Jäghult S, Eberhardson M, Nordenvall C, Björk J, Fagerberg UL, Rejler M, Grip O, Karling P, Block M, Angenete E, Hellström PM, Gustavsson A. Shrestha S, et al. Among authors: eriksson c. Scand J Gastroenterol. 2020 Apr;55(4):430-435. doi: 10.1080/00365521.2020.1740778. Epub 2020 May 6. Scand J Gastroenterol. 2020. PMID: 32370571 Free article.
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
Rundquist S, Sachs MC, Eriksson C, Olén O, Montgomery S, Halfvarson J; SWIBREG Study Group. Rundquist S, et al. Among authors: eriksson c. Aliment Pharmacol Ther. 2021 Feb;53(4):471-483. doi: 10.1111/apt.16193. Epub 2020 Dec 19. Aliment Pharmacol Ther. 2021. PMID: 33340426 Free PMC article.
520 results